BRASH syndrome as a clinical syndrome driven by polypharmacy: a pharmacovigilance study of 1,081 cases from FAERS

2026-01-16 emergency medicine Title + abstract only

Show abstract

BackgroundBRASH syndrome, characterized by bradycardia, renal failure, atrioventricular nodal blockade, shock, and hyperkalemia, is a recently described clinical entity that remains underrecognized. Current evidence is limited to case reports and small case series, and the pharmacological patterns underlying this syndrome have not been systematically evaluated. MethodsWe conducted a retrospective pharmacovigilance study using the U.S. Food and Drug Administration Adverse Event Reporting System ...

BRASH syndrome as a clinical syndrome driven by polypharmacy: a pharmacovigilance study of 1,081 cases from FAERS

Predicted journal destinations